CAMBRIDGE, Mass., Nov. 2 /PRNewswire/ -- Biogen (Nasdaq: BGEN) today
announced several new appointments in its International commercial
organization.
(Photo: http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO )
Robert A. Hamm has been named Senior Vice President-International,
replacing Mark Leuchtenberger, who has announced his intention to resign at
the end of this year. Mr. Hamm joined Biogen in 1994 and has played a
critical role in building the company's international commercial structure and
operating capability. Most recently, he was Vice President, Sales and
Marketing, where he was responsible for reinvigorating the growth rate of
AVONEX(R) (Interferon beta-1a), the company's flagship product. He has also
served as Vice President, Manufacturing, where he led development of Biogen's
global supply chain strategy, and was Biogen's Director of Northern Europe.
Guy-Charles Fanneau dela Horie has been named Vice President, Strategic
Commercial Operations-International. Mr. Fanneau dela Horie joined Biogen in
1995 as country manager responsible for launching AVONEX in France. Most
recently, he has been responsible for several assignments in the U.S.,
including the positions of National Sales Director and commercial program
executive for AVONEX.
Patrick Vink has been appointed Vice President, Sales, responsible for
International affiliates. Mr. Vink joined Biogen in 2000 as country manager,
Germany.
James C. Mullen, Biogen's President and Chief Executive Officer, said, "I
am delighted that this team is assuming leadership of our European
organization. Bob and Guy-Charles were responsible for the repositioning of
our U.S. commercial operations, resulting in reinvigoration of the AVONEX
market during the past year. They have both worked together before in the
European business. Our performance in Europe has been strengthened over the
past year, and I am confident that this team will accelerate that trend."
AVONEX is the world's leading therapy for the treatment of relapsing forms
of multiple sclerosis.
About Biogen
Biogen, Inc., winner of the U.S. National Medal of Technology, is a
biopharmaceutical company principally engaged in discovering and developing
drugs for human healthcare through genetic engineering. Headquartered in
Cambridge, MA, the Company's revenues are generated from international sales
of AVONEX for treatment of relapsing forms of multiple sclerosis, and from the
worldwide sales by licensees of a number of products, including alpha
interferon and hepatitis B vaccines and diagnostic products. (Please see full
prescribing information at http://www.avonex.com) Biogen's research and
development activities are focused on novel products to treat inflammatory and
autoimmune diseases, neurological diseases, cancer, fibrosis and congestive
heart failure. For copies of press releases and additional information about
the Company, please consult Biogen's Homepage on the World Wide Web at
http://www.biogen.com
SOURCE Biogen, Inc.
 back to top
Related links:
http://www.biogen.com.
Photo Notes:http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
Company News On-Call:
http://www.prnewswire.com/comp/101550.html
CONTACT:
Media: Kathleen O'Donnell, Associate
Director, Public Affairs, +1-617-679-2837, or Investment
Community: Elizabeth Woo, Associate Director, Investor Relations,
+1-617-679-2822, both of Biogen, Inc.
|
